DW-1002
Brilliant Blue G-250 (BBG250) is an ophthalmic surgical adjuvant whose active ingredient is a dye with high staining ability.
The dye temporarily and safely stains the capsule protecting the inner limiting membrane or crystalline lens in the back of the eye, making it easier to perform vitreous or cataract surgery.
BBG250 was discovered by a research group at Kyushu University, and has since been commercialized. DWTI acquired the business from Healios K.K. in 2017, and we have since been developing the dye under exclusive license from Kyushu University.
We have granted an exclusive sublicense for DW-1002 for all regions worldwide outside Japan to Dutch Ophthalmic Research Center (International) B.V. (DORC), which has been manufacturing and selling the product in Europe and other countries since September 2010.
Wakamoto Pharmaceutical Co., Ltd. has been granted an exclusive sublicense for Japan, and is moving forward with development aiming to obtain approval.
 |
|||||||
|---|---|---|---|---|---|---|---|
| ①ILM staining | ● in China | ● in Europe, U.S., etc. |
|||||
| ②ILM staining | ● in Japan | ||||||
| ③ALC staining | ● in Japan | ||||||
| ④ILM, ERM and PVR membrane staining | ● in Europe, etc. |
||||||
| ⑤ILM staining and ERM staining | ● in U.S. | ||||||
| Clinical indication |
①ILM staining (Europe, U.S., etc.) ②ILM staining (Japan) ③ALC staining (Japan) ④ILM, ERM and PVR membrane staining (Europe, etc.) ⑤ILM staining and ERM staining (U.S.) |
|---|---|
| Development process |
①Launched (Europe, U.S., etc.), Approve of new drug application (China) ②Phase III clinical trials (Japan) completed ③Phase III clinical trials (Japan) completed ④Launched (Europe, etc.) ⑤Phase III clinical trials (U.S.) |
| Licensee |
①Dutch Ophthalmic Research Center International B.V（DORC） ②③Wakamoto Pharmaceutical Co., Ltd. ④⑤Dutch Ophthalmic Research Center International B.V（DORC） |
Development Progress
- 2023.05Approve of new drug application (China)
- 2021.10Launched (Canada)
- 2021.01Approved of new drug application (Canada)
- 2020.04Launched (U.S.)
- 2017.04Acquired of business related to the ophthalmic surgical adjuvant
- 2010.09Launched (Europe)